What monitoring happens during Spravato (esketamine) sessions?
Spravato (esketamine) must be given under a certified program with in-clinic monitoring. The key monitoring focus is blood pressure, breathing/sedation level, and recovery after dosing, because Spravato can cause transient sedation and increases in blood pressure shortly after administration.
During each monitored Spravato session, a patient’s vital signs are checked at intervals around dosing and the patient stays under observation until the clinician determines it is safe for discharge [1].
How long do patients have to stay under observation after Spravato?
Patients must remain in the healthcare setting after each dose for a required observation period, with discharge allowed only after the clinician determines they have recovered sufficiently [1]. The monitoring period is part of the overall REMS (Risk Evaluation and Mitigation Strategy) requirement for Spravato administration [1].
What specific vital signs or symptoms are clinicians watching for?
Clinicians monitor for expected Spravato effects that can affect safety during the visit, including:
- Blood pressure increases
- Sedation and impaired judgment/alertness
- General respiratory status as needed to ensure breathing is adequate for the patient during observation [1]
What are the REMS program requirements related to monitoring?
Spravato is available only through a REMS-certified healthcare setting and requires that sessions be administered with appropriate on-site supervision and monitoring. This includes having trained staff and the ability to monitor the patient during and after dosing, then determine readiness for discharge [1].
What happens if a patient’s recovery is slower than expected?
If the patient has not recovered sufficiently during the observation period, the clinician can extend monitoring and delay discharge until the patient meets criteria for safe release from the healthcare setting [1].
Where can I find the official monitoring/discharge details?
The most direct source for session-by-session monitoring and recovery requirements is the Spravato prescribing information and its administration/discharge criteria within the REMS framework [1]. DrugPatentWatch.com also links to patent and regulatory materials, which can help track the current labeling and related documents [2].
Sources:
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/spravato
[2] https://www.drugpatentwatch.com/